Cargando…
Safety and immunogenicity of rabies vaccine (PVRV-WIBP) in healthy Chinese aged 10–50 years old: Randomized, blinded, parallel controlled phase III clinical study
This phase III clinical trial aimed to assess the safety and demonstrate the immunogenicity of a candidate freeze-dried purified Vero cell-based rabies vaccine (PVRV-WIBP) developed for human use. A cohort of 40 participants in stage 1 and 1956 subjects in stage 2 with an age range of 10–50 years we...
Autores principales: | Huang, Xiaoyuan, Liang, Jing, Huang, Lili, Nian, Xuanxuan, Chen, Wei, Zhang, Jiayou, Xu, Xiao, Lin, Xuan, Wang, Yue, Shi, Jinrong, Jia, Lanxin, Li, Qingliang, Wang, Qianxi, Duan, Kai, Li, Xinguo, Ji, Yaqi, Peng, Feixia, Zhang, Wei, Xie, Zhiqiang, Wang, Yanxia, Yang, Xiaoming |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10294720/ https://www.ncbi.nlm.nih.gov/pubmed/37249318 http://dx.doi.org/10.1080/21645515.2023.2211896 |
Ejemplares similares
-
Immunogenicity and tolerability of a bivalent virus-like particle norovirus vaccine candidate in children from 6 months up to 4 years of age: A phase 2 randomized, double-blind trial
por: López, Pio, et al.
Publicado: (2023) -
An open-label, Phase 3 trial of TAK-003, a live attenuated dengue tetravalent vaccine, in healthy US adults: immunogenicity and safety when administered during the second half of a 24-month shelf-life
por: Patel, Sanjay S., et al.
Publicado: (2023) -
Immunogenicity and safety of the non-typable Haemophilus influenzae–Moraxella catarrhalis (NTHi-Mcat) vaccine administered following the recombinant zoster vaccine versus administration alone: Results from a randomized, phase 2a, non-inferiority trial
por: Galgani, Ilaria, et al.
Publicado: (2023) -
Acceptability for the influenza virus vector COVID-19 vaccine for intranasal spray: A cross-sectional survey in Beijing, China
por: Ma, Yuan, et al.
Publicado: (2023) -
Safety and Immunogenicity of an Inactivated COVID-19 Vaccine, WIBP-CorV, in Healthy Children: Interim Analysis of a Randomized, Double-Blind, Controlled, Phase 1/2 Trial
por: Xia, Shengli, et al.
Publicado: (2022)